Industry News (Clinical Trials)

Enrollment of 2,500 Patients for Phase III Clinical Trial of Remune Completed

Published in AIDS Weekly, May 26th, 1997

The Immune Response Corporation, Carlsbad, California, announced that it has completed enrollment of its nationwide Phase III clinical trial of Remune, a therapy that fights HIV by stimulating the patient's own natural defense mechanisms against the virus.

This is the largest trial of an HIV-specific immune-based therapy ever conducted in the U.S. and involves 2,500 HIV infected individuals at 74 medical centers around the United States. The trial is designed to determine the effectiveness of Remune in slowing the progression of HIV infection to AIDS or death. Remune is the first treatment of its kind to advance to a Phase III clinical trial.

An...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1997-05-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry